Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

ABACAVIR FOR PEAK IDENTIFICATION CRS (10 MG)

ABACAVIR FOR PEAK IDENTIFICATION CRS (10 MG)

188062-50-2

DISCOVER
CICLESONIDE CRS (150 MG)

CICLESONIDE CRS (150 MG)

126544-47-6

DISCOVER
CICLESONIDE CONTAINING IMPURITY A CRS (15 MG)

CICLESONIDE CONTAINING IMPURITY A CRS (15 MG)

126544-47-6

DISCOVER
CICLESONIDE IMPURITY B CRS (10 MG)

CICLESONIDE IMPURITY B CRS (10 MG)

161115-59-9

DISCOVER
CICLESONIDE IMPURITY C CRS (10 MG)

CICLESONIDE IMPURITY C CRS (10 MG)

NA

DISCOVER
POLY(VINYL ACETATE) CRS (100 MG)

POLY(VINYL ACETATE) CRS (100 MG)

9003-20-7

DISCOVER
RISEDRONATE IMPURITY A CRS (10 MG)

RISEDRONATE IMPURITY A CRS (10 MG)

NA

DISCOVER
SALVIANOLIC ACID B CRS (15 MG)

SALVIANOLIC ACID B CRS (15 MG)

115939-25-8

DISCOVER
TANSHINONE IIA CRS (15 MG)

TANSHINONE IIA CRS (15 MG)

568-72-9

DISCOVER
ABACAVIR SULFATE CRS (20 MG)

ABACAVIR SULFATE CRS (20 MG)

188062-50-2

DISCOVER
DOXYLAMINE HYDROGEN SUCCINATECRS (60 MG)

DOXYLAMINE HYDROGEN SUCCINATECRS (60 MG)

562-10-7

DISCOVER
MESALAZINE IMPURITY A CRS (15MG)

MESALAZINE IMPURITY A CRS (15MG)

123-30-8

DISCOVER